1. Company Overview & Business Model

Novo Nordisk A/S is a global healthcare company with a century-long history of innovation, headquartered in Bagsværd, Denmark.¹ Founded through the merger of two Danish firms in 1989, the company has established itself as a dominant force in the treatment of serious chronic diseases.² Its business model is centered on the research, development, manufacturing, and commercialization of novel protein-based therapeutics, protected by a robust intellectual property portfolio and supported by large-scale, in-house manufacturing capabilities.⁴

Core Business Segments and Revenue Streams

The company’s operations are structured into two primary reporting segments: Diabetes and Obesity care and Rare disease.⁶

• Diabetes and Obesity Care: This segment is the undisputed engine of Novo Nordisk’s growth and profitability. In 2023, it generated DKK 215.1 billion in sales, representing approximately 93% of the company’s total revenue.⁷ This segment’s performance is overwhelmingly driven by its portfolio of Glucagon-Like Peptide-1 (GLP-1) receptor agonists, which have revolutionized the treatment paradigms for both type 2 diabetes and obesity. The success of these products has led to a strategic portfolio transition, where the high-growth GLP-1 franchise is increasingly supplanting the company’s legacy, but now slower-growing, insulin business.⁸ This internal cannibalization reflects a broader market shift towards more effective therapies that offer superior glycemic control alongside significant weight loss and, critically, proven cardiovascular and renal benefits.⁷ This evolution has effectively transformed the company’s core value proposition from simply treating diabetes to managing a spectrum of cardiometabolic health conditions.
• Rare Disease: This segment focuses on therapies for haemophilia and rare endocrine disorders, including growth disorders.¹¹ While considered a strategic priority for diversification, it is a much smaller contributor to the company’s overall performance, with sales of DKK 17.2 billion in 2023.⁷ The segment has recently faced headwinds, including sales declines attributed to temporary manufacturing output reductions, highlighting its sensitivity to supply chain disruptions.⁶

Key Products in Diabetes Care, Obesity Treatment, and Rare Diseases

The company’s value is highly concentrated in its semaglutide-based products, a single molecule marketed under three distinct brands:

• Ozempic®: A once-weekly injectable formulation of semaglutide approved for the treatment of type 2 diabetes. Its strong efficacy in lowering blood glucose and promoting weight loss has made it a global blockbuster and a primary driver of growth in the Diabetes and Obesity care segment.⁷
• Wegovy®: A higher-dose, once-weekly injectable formulation of semaglutide specifically approved for chronic weight management. The launch of Wegovy® unlocked the vast and underserved obesity market, generating unprecedented demand that has consistently outstripped the company’s manufacturing capacity.¹⁰
• Rybelsus®: The first and only oral formulation of a GLP-1 receptor agonist, offering a convenient alternative to injections for patients with type 2 diabetes. This product expands the addressable market by appealing to patients with a preference for oral therapies.¹²

Other key products include a comprehensive portfolio of insulins (Tresiba®, NovoLog®, Levemir®) and products for rare diseases such as haemophilia (NovoSeven®) and growth hormone deficiencies (Norditropin®).⁶

Geographic Revenue Breakdown and Key Markets

Novo Nordisk’s sales are divided into two major geographic regions: North America Operations (NAO) and International Operations (IO).⁷

• North America Operations: Comprising primarily the United States, NAO is the company’s largest and most critical market. In 2023, sales in NAO grew an astonishing 54% at constant exchange rates (CER), driven by the immense demand for Ozempic® and Wegovy®.⁷ This heavy reliance on the U.S. market represents a significant geographic concentration risk, making the company particularly vulnerable to U.S.-specific pricing pressures and regulatory changes.
• International Operations: This segment includes Europe, the Middle East, and Africa (EMEA), China, and the Rest of World. While also demonstrating strong performance with 16% CER growth in 2023, the growth rates are more modest than in NAO, reflecting different pricing, reimbursement landscapes, and stages of market development for GLP-1 therapies.⁷

Business Model Sustainability and Competitive Moats

Novo Nordisk’s business model is fortified by several powerful and reinforcing competitive moats:

1. Scientific Expertise and R&D Leadership: A century of focus on protein-based therapies has created a deep well of institutional knowledge, particularly in metabolic diseases. This expertise underpins a robust R&D engine that has consistently produced innovative products.⁴
2. Intellectual Property: A formidable patent portfolio, including a “thicket” of secondary patents on formulations and delivery devices, protects its key products from generic competition well into the next decade.¹⁶
3. Manufacturing Scale: The company’s massive, vertically integrated manufacturing infrastructure for biologics represents a significant capital barrier to entry. Ongoing multi-billion dollar investments are further widening this moat, making it exceedingly difficult for new entrants to compete on scale.¹⁸
4. Brand Equity and Commercial Infrastructure: Strong brand recognition for products like Ozempic® and Wegovy®, coupled with long-standing relationships with endocrinologists and a powerful global commercial footprint, creates a durable market presence.²⁰

2. Industry Dynamics & Market Position

Novo Nordisk operates at the epicenter of two of the largest and fastest-growing therapeutic markets in global healthcare: diabetes and obesity. The dynamics of these markets, shaped by demographic trends, scientific breakthroughs, and intense competition, are central to the company’s strategic context.

Global Diabetes and Obesity Treatment Market

• Diabetes Market: The global market for diabetes drugs was valued at approximately USD 88.3 billion in 2024 and is forecast to expand at a compound annual growth rate (CAGR) of 12.7%, reaching over USD 233 billion by 2032.²² This robust growth is underpinned by the escalating global prevalence of the disease, which is projected to affect 783 million adults by 2045, up from 537 million in 2021.²² Factors driving this pandemic include rising rates of obesity, sedentary lifestyles, and aging populations.
• Obesity Market: The market for obesity treatments is experiencing a period of hyper-growth, catalyzed by the launch of highly effective GLP-1 therapies. Valued at approximately USD 15.9 billion in 2024, the market is projected to grow at an explosive CAGR of over 22%, reaching more than USD 60 billion by 2030.²⁴ Some industry forecasts are even more optimistic, projecting a potential market size of USD 150 billion by 2035, reflecting the vast, untapped patient population and the paradigm shift in viewing obesity as a treatable chronic disease.²⁵

Market Share and Competitive Landscape

While Novo Nordisk has long been the established leader in diabetes care, the competitive landscape has been radically reshaped into a dynamic duopoly.

• Market Leadership: Novo Nordisk maintains a leading global value market share in the overall diabetes market, at 33.8% as of year-end 2023.⁷ Within the critical GLP-1 class, it has historically held a dominant position, with a volume share of 63% in 2024.¹³
• The Duopoly with Eli Lilly: The primary competitive threat comes from Eli Lilly (LLY), whose dual GIP/GLP-1 agonist tirzepatide (marketed as Mounjaro® for diabetes and Zepbound® for obesity) has demonstrated remarkable commercial success and, in some head-to-head trials, superior weight-loss efficacy compared to semaglutide.¹⁴ Driven by the rapid uptake of its products, Eli Lilly reportedly surpassed Novo Nordisk in overall new-to-brand GLP-1 market share in the U.S. in early 2025, capturing 53%.²⁷ This intense rivalry defines the market, with both companies investing heavily in manufacturing, R&D, and commercial activities to gain an edge.
• Other Competitors: Sanofi (SNY) remains a significant player in the legacy insulin market but currently lacks a competitive offering in the high-growth GLP-1 obesity space.²⁸ A host of other large pharmaceutical and biotechnology companies, such as Amgen and Viking Therapeutics, are also developing next-generation obesity treatments, which could lead to greater market fragmentation in the long term.²⁹

The current market dynamic is unique. With demand for GLP-1s far exceeding the combined supply of both Novo Nordisk and Eli Lilly, the near-term environment is not a zero-sum game.¹⁰ Both companies are able to grow revenues at an exceptional rate by collectively expanding the market and bringing new patients onto therapy. However, this phase is temporary. As manufacturing capacity scales up over the next several years, the competition will inevitably shift from a race to produce, to a head-to-head battle for market share based on product differentiation—including efficacy, tolerability, convenience (oral vs. injectable), and ultimately, price.

Regulatory Environment and Patent Landscape

The industry operates under the strict oversight of regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A key strategic imperative is securing label expansions for existing drugs based on positive outcomes trials, such as the cardiovascular risk reduction indication for Wegovy® following the SELECT trial, as this significantly enhances a product’s value proposition to both physicians and payers.⁷

The patent landscape is of paramount importance. Novo Nordisk’s key composition of matter patent for semaglutide is expected to expire in the U.S. and Europe around 2031-2032.¹⁶ This looming “patent cliff” represents the single largest long-term risk to the company. To mitigate this, Novo Nordisk, like its peers, employs a strategy of building a “patent thicket”—a dense web of secondary patents covering manufacturing processes, drug formulations, and delivery devices—to delay the entry of generic and biosimilar competitors for as long as possible.¹⁶

Barriers to Entry

The barriers to entry in the innovative diabetes and obesity markets are exceptionally high, protecting the incumbents. These include:

• Prohibitive R&D Costs: The cost of discovering, developing, and running global Phase 3 outcomes trials for a new metabolic drug can run into the billions of dollars.
• Complex Manufacturing: The production of complex biologics like GLP-1s requires specialized expertise and massive capital investment in manufacturing facilities, a barrier that Novo Nordisk and Eli Lilly are actively raising through their multi-billion dollar capacity expansions.¹⁸
• Clinical Data Moat: Gaining regulatory approval and, crucially, broad reimbursement requires extensive clinical data, including long-term cardiovascular outcomes trials. Generating this data takes years and significant investment, creating a substantial time and cost advantage for established players.

3. Competitive Advantages & Strategic Position

Novo Nordisk’s market leadership is built on a foundation of distinct and mutually reinforcing competitive advantages that have been cultivated over decades. These strengths position the company to compete effectively in the highly dynamic cardiometabolic market.

Patent Portfolio and Pipeline Protection

Intellectual property is the lifeblood of any innovative pharmaceutical company, and Novo Nordisk maintains a robust and actively managed patent portfolio. The core composition of matter patent for semaglutide provides market exclusivity in the U.S. until December 2031, with similar timelines in other major markets.¹⁶ Beyond this primary patent, the company has constructed a formidable “patent thicket,” securing numerous secondary patents on specific formulations (such as the oral delivery technology in Rybelsus®), methods of use for new indications, and the proprietary technology embedded in its pen-injector devices.¹⁷ This layered IP strategy is designed to create legal hurdles that can delay the launch of generic or biosimilar versions well beyond the expiration of the core patent.

Manufacturing Capabilities and Supply Chain Advantages

In the current supply-constrained GLP-1 market, manufacturing has evolved from a support function into a core strategic weapon. Novo Nordisk’s capabilities in this domain represent a powerful competitive advantage. As the world’s largest producer of insulin and GLP-1s, the company possesses deep institutional expertise in the complex processes of fermentation, purification, and sterile fill-finish for biologic drugs at an immense scale.¹⁸

Recognizing that production capacity is the primary bottleneck to growth, the company has embarked on an unprecedented capital expenditure program, committing over DKK 129 billion in 2024 alone to expand its global manufacturing footprint.¹³ This includes massive expansions of existing sites in Denmark and the U.S., as well as the strategic acquisition of three fill-finish facilities from Catalent to accelerate the scaling of its injectable drug supply.¹³ This aggressive investment in vertical integration not only aims to meet overwhelming demand but also serves to build a formidable manufacturing moat, raising the capital and technical barriers for any competitor seeking to challenge its scale.

R&D Capabilities and Innovation Track Record

With a legacy of innovation stretching back 100 years, Novo Nordisk’s R&D organization is a key pillar of its strategic position.² The company has successfully navigated multiple technology cycles within diabetes care, from animal-derived insulins to human insulins, modern insulin analogues, and now the era of incretin-based therapies.

The current R&D approach is increasingly sophisticated, integrating cutting-edge technology platforms to enhance productivity. The company is leveraging artificial intelligence and machine learning to mine vast datasets from its clinical trials (such as the SELECT study) to identify novel drug targets and biomarkers.³⁶ Furthermore, strategic acquisitions and partnerships, such as the purchase of Dicerna Pharmaceuticals, have brought in new technological capabilities like RNA interference (RNAi), opening up new avenues for treating diseases by targeting intracellular pathways that are inaccessible to traditional protein therapies.³⁶ The R&D pipeline is a testament to this innovative capacity, with next-generation multi-agonist therapies like CagriSema and amycretin aiming to once again raise the bar for efficacy in metabolic disease.³⁰

Brand Recognition and Physician Relationships

Decades of singular focus on diabetes have allowed Novo Nordisk to build unparalleled brand equity and deep, trusted relationships with the key prescribers in the field, including endocrinologists and primary care physicians.²¹ This established commercial presence provides a significant advantage when launching new products.

Moreover, the GLP-1 phenomenon has transcended traditional medical marketing. The brand names Ozempic® and Wegovy® have achieved a level of consumer awareness rarely seen in the prescription drug market, fueled by media coverage and social media.²⁰ This has created a powerful patient-driven “pull” effect, where patients actively request the drugs by name. This dynamic mirrors the company’s past success with the NovoPen®, where a focus on the patient’s needs for convenience and ease of use created a new market dynamic.²¹ This powerful brand recognition pressures healthcare providers to prescribe and payers to provide reimbursement, solidifying the company’s commercial position.

Regulatory Expertise and Approval Track Record

Novo Nordisk has a long and successful history of navigating the complex global regulatory landscape. The company has demonstrated a core competency in designing and executing large-scale, long-term cardiovascular outcomes trials (CVOTs). The success of trials like LEADER (for Victoza®) and SELECT (for Wegovy®) is a critical differentiator, providing the high-quality evidence needed to secure not only initial approvals but also valuable label expansions for cardiovascular risk reduction.⁷ This ability to prove that its medicines save lives and reduce costly healthcare events is essential for justifying premium pricing and securing broad market access from increasingly cost-conscious payers.

4. Financial Performance & Growth Analysis

Novo Nordisk’s financial performance over the past decade has been characterized by a dramatic inflection in growth and profitability, driven almost entirely by the commercial success of its GLP-1 franchise. The company exhibits best-in-class financial metrics, reflecting its dominant market position and the high value of its innovative products.

Revenue, Earnings, and Margin Trends

An analysis of the company’s financial history reveals a period of steady, single-digit to low-double-digit growth, followed by an explosive acceleration beginning in 2021. Revenue growth surged from 6.3% in 2020 to 34.6% in 2023, with continued strong growth of 24.9% reported for 2024.⁴¹ This top-line momentum has translated into exceptional profitability. The company consistently maintains gross profit margins above 84%, a testament to its efficient manufacturing and strong pricing power.⁴² More impressively, significant operating leverage has driven the operating profit margin to over 44% and the net profit margin to over 36% in recent years, placing Novo Nordisk among the most profitable companies in the pharmaceutical industry.⁴³

Table 1: 10-Year Financial Summary (in billion DKK)

Fiscal Year	Revenue	Revenue Growth	Gross Profit	Gross Margin	Operating Income	Operating Margin	Net Income	Net Margin
2015	108.0	–	89.9	83.2%	49.4	45.7%	34.9	32.3%
2016	111.8	3.5%	94.0	84.1%	49.3	44.1%	37.9	33.9%
2017	111.7	-0.1%	93.3	83.5%	48.9	43.8%	38.1	34.1%
2018	113.1	1.3%	94.8	83.8%	48.9	43.2%	39.0	34.5%
2019	122.0	7.9%	101.9	83.5%	52.5	43.0%	39.0	31.9%
2020	126.9	4.0%	106.0	83.5%	54.1	42.6%	42.1	33.2%
2021	140.8	10.9%	117.1	83.2%	58.6	41.6%	47.8	33.9%
2022	177.0	25.7%	148.5	83.9%	74.8	42.3%	55.5	31.4%
2023	232.3	31.3%	196.5	84.6%	102.6	44.2%	83.7	36.0%
2024 (Est.)	290.4	25.0%	245.9	84.7%	130.0	44.8%	101.0	34.8%
Note: Data compiled and synthesized from multiple sources including annual reports and financial data providers. 2024 figures are based on full-year results where available. Margins are calculated from source data. Sources:.7

Segment Performance Analysis

A breakdown of performance by segment underscores the company’s increasing reliance on its Diabetes and Obesity care franchise. While this segment has delivered spectacular growth, the Rare disease segment has contracted, reducing its contribution to the overall business and offering limited diversification benefits in its current state.

Table 2: Segment Performance Analysis (in billion DKK)

	2021	2022	2023	H1 2024
Diabetes & Obesity Care
Net Sales	121.6	156.7	215.1	125.0
Sales Growth (CER)	13%	20%	42%	27%
Operating Profit	55.4	72.8	102.9	60.1
Operating Margin	45.5%	46.5%	47.8%	48.0%
Rare Disease
Net Sales	19.2	20.3	17.2	8.4
Sales Growth (CER)	5%	1%	-15%	-3%
Operating Profit	3.2	2.0	-0.3	-1.1
Operating Margin	16.9%	9.8%	-1.8%	-13.1%
Note: Data compiled from company financial reports. H1 2024 is for the first six months of the year. Operating profit for segments is before unallocated items. Sources:.7

Return on Invested Capital (ROIC) and Return on Equity (ROE)

Novo Nordisk has historically generated exceptionally high returns on capital, a hallmark of a company with a strong and sustainable competitive advantage. For the full year 2023, the company reported a Return on Equity (ROE) of 83.8% and a Return on Invested Capital (ROIC) of 66.3%.⁴⁶ These world-class figures indicate that the company has been able to generate substantial profits from the capital invested in the business by shareholders and lenders.

However, these stellar historical metrics must be viewed with caution. They were generated on a capital base that was established before the current period of massive reinvestment. The company is now in a CAPEX “supercycle,” deploying tens of billions of dollars into new manufacturing facilities.⁴⁸ This will dramatically increase the “Invested Capital” and “Equity” denominators used in these calculations. While profits are also growing, it is mathematically very difficult to maintain such high return rates on a much larger and rapidly expanding capital base. Investors should therefore anticipate a gradual normalization of these metrics from their current stratospheric levels to what would still be considered excellent, but more sustainable, levels for the industry.

Cash Flow Generation and Balance Sheet Strength

The company’s business model is highly cash-generative. Cash flow from operating activities has grown robustly, reaching DKK 108.9 billion in 2023.⁴⁴ This strong operating cash flow comfortably funds R&D, capital expenditures, and returns to shareholders. Free cash flow stood at a healthy DKK 68.3 billion in 2023.⁴⁴

The balance sheet is strong and provides ample capacity for further investment. As of year-end 2023, total assets were DKK 314.5 billion against total equity of DKK 106.6 billion, resulting in a solid equity ratio of 33.9%.¹⁰ While debt levels have increased to help fund the significant CAPEX program and strategic acquisitions, the company’s leverage ratios remain conservative and well within manageable limits.⁴⁵

5. Growth Drivers & Opportunities

Novo Nordisk is positioned at the forefront of a major secular growth trend in healthcare. The company’s future growth trajectory will be determined by its ability to capitalize on the expanding GLP-1 market, successfully execute on its deep R&D pipeline, and penetrate new geographic markets.

GLP-1 Market Opportunity

The primary growth driver for Novo Nordisk is the continued global adoption of GLP-1 therapies. The opportunity extends across several dimensions:

• Obesity Market Penetration: The global obesity market remains in its infancy. With over 800 million people worldwide living with obesity and only a small fraction currently receiving medical treatment, the runway for growth for effective therapies like Wegovy® is immense.²⁴
• Expansion into New Indications: The therapeutic potential of GLP-1s extends beyond diabetes and weight loss. Positive clinical trial data is emerging for the treatment of related co-morbidities such as Metabolic dysfunction-associated steatohepatitis (MASH), cardiovascular disease, and chronic kidney disease.⁷ Each successful label expansion would significantly increase the total addressable market and further entrench semaglutide as a foundational therapy in cardiometabolic medicine. There is also early-stage research exploring its potential in neurodegenerative diseases like Alzheimer’s.⁴⁰

Pipeline Analysis

The company’s long-term value is heavily dependent on its R&D pipeline, which is designed to extend its leadership in metabolic diseases and defend its franchise against both competitors and the eventual patent expiration of semaglutide. The pipeline strategy is focused on “mechanism stacking”—combining the GLP-1 mechanism with other biological pathways to achieve even greater efficacy. While this approach holds the promise of creating next-generation, best-in-class therapies, it also introduces a higher degree of clinical and biological risk compared to single-agonist drugs.

Table 3: Key Pipeline Assets Summary

Drug Candidate	Mechanism of Action	Target Indication(s)	Development Phase	Key Differentiator/Commentary
CagriSema	Semaglutide (GLP-1) + Cagrilintide (Amylin analogue)	Obesity, Type 2 Diabetes	Phase 3	Co-administered dual-mechanism therapy. Phase 3 data showed 22.7% weight loss, positioning it as a direct competitor to Lilly’s tirzepatide.13
Amycretin	Unimolecular GLP-1 / Amylin co-agonist	Obesity, Type 2 Diabetes	Phase 2 (SubQ), Phase 1 (Oral)	Highly promising next-generation asset. Early data showed exceptional weight loss (13.1% oral at 12 wks; 22.0% SubQ at 36 wks), exciting the market.13
Oral Semaglutide	GLP-1 Receptor Agonist	Obesity, Type 2 Diabetes	Phase 3 (50mg)	Higher oral doses aim to achieve weight loss efficacy comparable to injectable Wegovy®, expanding patient convenience and market access.7
Insulin Icodec	Ultra-long-acting basal insulin analogue	Type 1 & 2 Diabetes	Filed	The first once-weekly basal insulin, designed to improve adherence and quality of life in the mature insulin market.10
Ziltivekimab	IL-6 inhibitor (mAb)	Cardiovascular Disease (ASCVD, HFpEF)	Phase 3	A move beyond metabolic disease, targeting inflammation as a driver of cardiovascular risk. Acquired asset.10
Mim8	Bi-specific antibody (mimics Factor VIIIa)	Haemophilia A	Phase 3	A next-generation therapy for the Rare Disease franchise, offering potential for less frequent dosing.10
Note: Pipeline status is dynamic and subject to change. Data compiled from company presentations and pipeline trackers. Sources:.10

Geographic Expansion Opportunities

While North America is the current growth engine, significant long-term opportunities lie in international markets.

• Europe: The launch of Wegovy® in key European markets like the UK and Germany has been met with strong demand, though constrained by supply. Securing broader reimbursement across the continent is a key priority and opportunity.⁵¹
• China: With an estimated 184 million people living with obesity, China represents a massive potential market. The regulatory decision for Wegovy® is expected in 2024, which could unlock a major new avenue for growth.⁵¹
• Other Emerging Markets: As economies develop and healthcare spending increases, the prevalence of diabetes and obesity is rising rapidly in many low- and middle-income countries, creating long-term growth potential.⁵

Digital Health and Technology Integration

There is a growing opportunity to create a more comprehensive “ecosystem” of care around Novo Nordisk’s therapies. This could involve partnerships or in-house development of digital health tools, such as mobile apps, connected devices, and wearable sensors, to help patients manage their condition, improve adherence, and track outcomes.³⁶ Such an ecosystem could increase patient loyalty and provide valuable real-world data to further refine treatment strategies.

6. Key Risks & Challenges

Despite its formidable market position and exceptional growth, Novo Nordisk faces a range of significant risks that could impact its long-term value. These challenges span competitive, regulatory, operational, and clinical domains.

Patent Cliff Exposure and Revenue Concentration

The single greatest long-term risk is the company’s profound dependence on the semaglutide franchise (Ozempic®, Wegovy®, Rybelsus®). With the core patents set to expire in the early 2030s, Novo Nordisk faces a monumental patent cliff.¹⁶ The failure of its R&D pipeline to deliver one or more new blockbuster products to offset the eventual erosion of semaglutide sales would have severe consequences for revenue and profitability. This high degree of product and therapeutic area concentration makes the company’s valuation highly sensitive to the long-term outlook for the GLP-1 market and its ability to innovate beyond it.

Competitive Threats from Biosimilars and New Entrants

The primary competitive threat is immediate and intense. Eli Lilly’s dual-agonist tirzepatide (Mounjaro®/Zepbound®) has already proven to be a formidable challenger, rapidly gaining market share and demonstrating superior efficacy in some clinical comparisons.²⁶ The long-term battle for market leadership will be fought on the grounds of next-generation product superiority. A key risk is that a competitor—whether Eli Lilly with its own advanced pipeline or another player—develops a therapy with a demonstrably better profile in terms of efficacy, safety, or convenience. For instance, while the market is currently focused on achieving the highest percentage of weight loss, a competitor’s product that is “good enough” on efficacy but offers superior tolerability or the convenience of a daily oral pill could capture significant market share from a more potent but less user-friendly injectable.²⁷

Manufacturing and Supply Chain Risks

The unprecedented demand for its GLP-1 products has placed immense strain on Novo Nordisk’s manufacturing and supply chain, a situation the company acknowledges has led to periodic constraints and drug shortages.⁷ To address this, the company has embarked on a massive global expansion of its production capacity.¹⁹ This strategy, while necessary, is fraught with execution risk. Large-scale biopharmaceutical manufacturing projects are notoriously complex, capital-intensive, and prone to delays, quality control issues, and cost overruns.⁵² Any significant setback in bringing this new capacity online in a timely and compliant manner would directly cap the company’s revenue growth potential.

Regulatory Risks and Pricing Pressure

As a global pharmaceutical leader, Novo Nordisk is subject to stringent regulatory oversight and increasing pricing pressure from governments and private payers worldwide. In the U.S., its largest market, the Inflation Reduction Act (IRA) introduces the prospect of government price negotiation for drugs covered by Medicare, which could erode long-term profitability.⁵³ Furthermore, securing and maintaining broad, unrestricted reimbursement for obesity treatments remains a challenge, as some payers are hesitant to cover what they may still perceive as “lifestyle” drugs, despite growing evidence of their health benefits.⁵¹

Clinical Trial Failures and Pipeline Setbacks

The company’s strategy for growth beyond semaglutide is entirely dependent on the success of its R&D pipeline. The high valuation of the company’s stock reflects significant optimism about late-stage assets like CagriSema and early-stage programs like amycretin. A failure of any of these key programs in pivotal clinical trials—due to insufficient efficacy, an unfavorable safety profile, or other issues—would severely undermine the long-term growth narrative and could lead to a significant re-rating of the stock.⁵⁵

Currency and Administrative Risks

With operations in 80 countries and sales in 170, the company has significant exposure to foreign currency fluctuations, which can impact reported financial results.¹³ Additionally, the recent lapse of a key semaglutide patent in Canada due to an administrative failure to pay a small maintenance fee highlights the potential for operational and human errors to have significant financial consequences.⁵⁷

7. Capital Allocation & Shareholder Returns

Novo Nordisk’s capital allocation strategy reflects the long-term perspective of its controlling shareholder, the Novo Nordisk Foundation, and has recently undergone a significant pivot to support a period of unprecedented growth. The company’s philosophy prioritizes reinvestment in the business to drive sustainable, long-term value creation, while also providing attractive returns to shareholders.

Historical Capital Allocation Priorities

The company’s stated capital allocation priorities are hierarchical:

1. Invest in internal growth opportunities: This includes funding the R&D pipeline and capital expenditures (CAPEX) for manufacturing.
2. Pay an attractive annual dividend.
3. Pursue value-accretive business development (M&A): Primarily focused on enhancing the R&D pipeline.
4. Distribute excess cash to shareholders via share buybacks.⁵⁸

Historically, this has resulted in a balanced approach. However, the explosive demand for GLP-1 therapies has triggered a dramatic strategic shift. Investment in CAPEX has become the overwhelming top priority, with planned expenditures quadrupling since 2021 to support the massive scale-up of production capacity.⁵¹ In 2024, CAPEX reached DKK 47.2 billion, and it is expected to rise to around DKK 65 billion in 2025, reflecting the critical need to build out the global supply chain.⁴⁸

Dividend Policy and Sustainability

Novo Nordisk has a strong and consistent track record of returning capital to shareholders through dividends. The company aims for a stable dividend payout ratio and has consistently grown its dividend per share.⁴⁵ For the 2023 fiscal year, the total proposed dividend was DKK 9.40 per share.⁷ Given the company’s robust earnings growth and strong cash flow generation, the dividend appears highly sustainable and is likely to continue growing, even with the elevated levels of reinvestment.

M&A Strategy and Track Record

The company’s M&A strategy has traditionally focused on smaller, bolt-on acquisitions designed to augment its internal R&D capabilities. This includes acquiring early-stage pipeline assets in adjacent therapeutic areas (e.g., ocedurenone for hypertension) or gaining access to novel technology platforms (e.g., the acquisition of Dicerna Pharmaceuticals for its RNAi technology).¹⁰ The company has generally avoided large, transformative mergers.

A notable recent development, however, was the acquisition of three fill-finish manufacturing sites from Catalent for USD 11.7 billion, executed via Novo Holdings.¹³ This transaction represents a significant strategic pivot. Rather than acquiring R&D assets, this deal is a form of vertical integration aimed squarely at securing and accelerating the expansion of its manufacturing capacity.¹⁹ It signals a recognition that in the current supply-constrained market, control over the supply chain is a critical competitive advantage, and the company is willing to deploy significant capital to secure it.

Management’s Capital Allocation Philosophy

The management’s approach is deeply influenced by the Novo Nordisk Foundation’s mandate to ensure the long-term stability and success of the company.¹³ This allows for a focus on long-term value creation over short-term financial engineering. The current strategy of aggressively reinvesting the windfall profits from the GLP-1 franchise back into R&D and manufacturing capacity is a clear embodiment of this philosophy. It is a deliberate choice to fortify the company’s competitive moats and build the foundation for the next decade of growth, rather than maximizing immediate shareholder returns through larger buybacks or dividends.⁵⁸

8. Management Quality & Corporate Governance

The quality of a company’s leadership and the integrity of its governance structure are critical determinants of long-term success. Novo Nordisk is characterized by an experienced management team and a unique governance model shaped by its foundation ownership.

Leadership Team Track Record and Strategic Vision

The executive management team at Novo Nordisk is considered experienced, with an average tenure of 3.3 years.⁶¹ Under the leadership of President and CEO Lars Fruergaard Jørgensen, who was appointed in January 2017, the company has experienced a period of historic transformation and growth.⁶¹ Jørgensen’s tenure has been defined by the successful commercialization of the semaglutide franchise, which propelled Novo Nordisk to become the most valuable company in Europe and a global leader in the treatment of obesity.⁶³ This track record demonstrates a strong capacity for strategic execution and navigating a complex, high-growth market.

However, in May 2025, the company announced that Jørgensen would be stepping down, following a mutual agreement with the board.⁶⁴ This decision came after a period of share price decline and was reportedly influenced by the Novo Nordisk Foundation seeking a more active role in the company’s strategic direction.⁶³ This leadership transition, occurring at a peak of commercial success, introduces a degree of uncertainty and signals a potential strategic recalibration as the company confronts intensifying competition and prepares for its long-term future.

Corporate Governance Practices

Novo Nordisk operates with a two-tier management structure, comprising a Board of Directors and an Executive Management team, with no overlapping members.⁶⁵ The company adheres to the Danish Corporate Governance Recommendations and the standards of the NYSE for foreign private issuers.⁶⁶ The Board is responsible for overall strategy and supervision, while Executive Management handles daily operations. The Board is composed of shareholder-elected and employee-elected members and is supported by several specialized committees, including Audit, People and Governance, Remuneration, and Research & Development committees.⁶⁶

The Role of the Novo Nordisk Foundation

The company’s governance is fundamentally shaped by its ownership structure. The Novo Nordisk Foundation, through its wholly-owned holding company Novo Holdings A/S, controls 77.28% of the voting rights in Novo Nordisk A/S.⁶⁶ The Foundation has a dual mandate: to provide a stable basis for the commercial activities of the Novo Group companies and to support scientific and humanitarian causes.⁶⁶

This controlling ownership provides a significant strategic advantage. It insulates the company from the pressures of short-term market fluctuations and activist investors, enabling management to make bold, long-term investments, such as the current multi-billion dollar manufacturing expansion.¹³ However, it also creates a unique power dynamic. The Foundation’s increased involvement, exemplified by the return of its chairman (and former Novo Nordisk CEO) Lars Rebien Sørensen to the company’s board meetings as an observer, underscores its ultimate authority in setting the long-term strategic agenda.⁶³ The recent CEO change can be interpreted as a proactive move by the Foundation to ensure the company’s leadership is aligned with its vision for navigating the next phase of growth, which may involve a greater focus on diversification and long-term risk management beyond the current GLP-1 boom.

Insider Ownership and Alignment with Shareholders

Insider ownership among the executive team is relatively low as a percentage of total shares outstanding. CEO Lars Fruergaard Jørgensen directly owns approximately 0.015% of the company’s shares.⁶² The alignment of management’s interests with those of shareholders is primarily achieved through performance-based incentive programs. Executive remuneration includes short-term cash bonuses and long-term share-based incentives that are tied to the achievement of the company’s Strategic Aspirations 2025, which encompass financial, commercial, and sustainability targets.¹³

9. Valuation Analysis

Assessing the valuation of Novo Nordisk requires balancing its extraordinary growth profile and best-in-class profitability against the high expectations embedded in its stock price and the significant long-term risks it faces. The company trades at a premium to both its historical averages and the broader pharmaceutical sector, a valuation that is contingent on near-flawless execution in the coming years.

Current Trading Multiples vs. Historical Ranges

Novo Nordisk’s valuation multiples have expanded significantly in recent years, reflecting the market’s recognition of its explosive growth prospects. The stock’s trailing Price-to-Earnings (P/E) ratio currently stands in the range of 19-21x, with a forward P/E ratio of approximately 15-17x based on consensus earnings estimates.⁶⁷ This is notably higher than the company’s 10-year average P/E of around 27x, though recent market conditions have seen some compression.⁶⁹ Similarly, the Enterprise Value to EBITDA (EV/EBITDA) multiple is in the 13-15x range, which is also elevated compared to historical norms from before the GLP-1 surge.⁶⁷ This premium valuation indicates that the market has already priced in a substantial amount of future growth.

Peer Comparison Analysis

A comparison with its peers provides critical context for Novo Nordisk’s valuation. The most relevant peer is Eli Lilly, given their direct competition and similar high-growth profiles. The broader pharmaceutical sector, represented by companies like Sanofi, provides a benchmark for more mature, slower-growing businesses.

Table 4: Valuation Multiples vs. Historical and Peers

Metric	Novo Nordisk (NVO)	NVO (5-Yr Avg)	Eli Lilly (LLY)	Sanofi (SNY)
P/E Ratio (Trailing)	~20.7x	~32.4x	~43.4x	~12.3x
P/E Ratio (Forward)	~16.6x	N/A	~46.4x	N/A
EV/EBITDA (Trailing)	~14.5x	~24.5x	~36.2x	~4.6x
Price/Sales (Trailing)	~7.2x	~9.9x	~14.9x	~2.6x
Dividend Yield (%)	~2.3%	~1.6%	~0.7%	~4.2%
Note: Data is indicative and compiled from multiple sources as of mid-2025. Multiples are subject to market fluctuations. Sources:.14

The analysis reveals several key points:

• Novo Nordisk trades at a significant premium to mature pharmaceutical companies like Sanofi, which is justified by its vastly superior growth rate.
• Compared to its chief rival, Eli Lilly, Novo Nordisk’s valuation appears more modest. Eli Lilly commands a much higher P/E and EV/EBITDA multiple, suggesting the market may be pricing in even more aggressive growth or a higher probability of success for its pipeline.

Discounted Cash Flow (DCF) Modeling Considerations

A DCF valuation for Novo Nordisk would be highly sensitive to a few key assumptions:

• Revenue Growth: High double-digit growth (20%+) would be modeled for the next 3-5 years, followed by a gradual deceleration as the market matures and competition intensifies.
• Terminal Growth: The assumption for the terminal growth rate post-2032 would be critical, as it must account for the significant revenue impact of the semaglutide patent cliff.
• Profitability: Operating margins are likely to be modeled at or near current high levels, reflecting the company’s efficiency and pricing power.
• Capital Expenditures: A significant deviation from historical norms, with CAPEX modeled as a much higher percentage of sales in the near term to reflect the ongoing manufacturing expansion.

Scenario Analysis and Valuation Discussion

The current valuation appears to be pricing in a scenario of near-perfect execution. It assumes that Novo Nordisk will successfully scale its manufacturing to meet the vast majority of near-term demand and that its pipeline will deliver a successful successor to semaglutide, allowing the company to defend its market share against Eli Lilly and navigate the patent cliff without a catastrophic drop in revenue.

• Bull Case: The market for obesity drugs proves to be even larger than current optimistic forecasts. CagriSema and/or amycretin demonstrate clear superiority over competing products, solidifying Novo Nordisk’s leadership for another decade. Successful label expansions into MASH and other areas add further layers of growth.
• Bear Case: Manufacturing scale-up hits significant snags, ceding near-term market share to Eli Lilly. The pipeline falters, with CagriSema failing to show a compelling advantage over Zepbound or amycretin encountering safety or efficacy issues in later-stage trials. Aggressive government price controls are implemented, severely compressing margins. In this scenario, the current valuation would be unsustainable.

The high valuation leaves little margin for error. Any significant stumble on the operational or clinical front could lead to a substantial de-rating of the stock, as the growth assumptions underpinning the premium multiple would be called into question.

10. Key Metrics to Monitor

To effectively track the investment thesis for Novo Nordisk, investors should closely monitor a specific set of leading indicators and upcoming catalysts. These metrics provide real-time insight into the company’s competitive positioning, operational execution, and pipeline progress.

• Market Share Trends in Core Therapeutic Areas:

• Metric: Weekly and monthly new-to-brand (NBRx) and total prescriptions (TRx) data for Wegovy® vs. Zepbound® and Ozempic® vs. Mounjaro®, particularly in the U.S. market.
• Rationale: This is the most direct, high-frequency indicator of the competitive dynamic with Eli Lilly and is crucial for assessing market share shifts.
• Pipeline Progression and Regulatory Milestones:

• Catalysts: Top-line data readouts from pivotal Phase 3 trials for CagriSema in obesity and diabetes. Phase 2 data for amycretin.
• Milestones: Regulatory submission and approval dates for higher-dose oral semaglutide, insulin icodec, and potential label expansions for Wegovy® based on outcomes data (e.g., MASH).
• Rationale: The company’s long-term value is contingent on its pipeline. Positive trial results are key validation points, while delays or failures represent significant risks.
• Pricing Trends and Reimbursement Changes:

• Metric: Updates on formulary status and tiering for Wegovy® and Ozempic® with major U.S. Pharmacy Benefit Managers (PBMs).
• Events: Announcements of reimbursement decisions in key international markets (e.g., UK’s NICE, Germany’s G-BA, China’s NRDL). Any developments related to the U.S. Inflation Reduction Act (IRA) price negotiations.
• Rationale: Market access is a critical determinant of volume growth. Favorable reimbursement decisions unlock large patient populations, while pricing pressures can erode profitability.
• Manufacturing Capacity Utilization and Expansion:

• Metric: Company guidance on supply constraints, updates on the operational status of manufacturing facilities (including the newly acquired Catalent sites), and forward-looking capital expenditure forecasts.
• Rationale: In the current supply-constrained environment, production capacity is a primary driver of revenue. Monitoring the progress of the manufacturing scale-up is essential to gauge the company’s ability to meet demand.
• Geographic Expansion Progress:

• Metric: Reported sales growth in International Operations, with a specific focus on performance in newly launched markets for Wegovy® in Europe and the ramp-up in China post-approval.
• Rationale: International markets represent the next major frontier for growth. Tracking early launch trajectories provides insight into the long-term global potential of the obesity franchise.
• R&D Productivity Metrics:

• Metric: The number of new molecular entities entering Phase 1 clinical trials annually.
• Rationale: This serves as a leading indicator of the health and productivity of the early-stage R&D engine, which is vital for ensuring a sustainable pipeline beyond the current late-stage assets.

Works cited

1. Novo Nordisk A/S (NVO): history, ownership, mission, how it works & makes money – dcfmodeling.com, accessed July 25, 2025, https://dcfmodeling.com/blogs/history/nvo-history-mission-ownership
2. Our heritage | Novo Nordisk | Driving change, accessed July 25, 2025, https://www.novonordisk.com/about/our-heritage.html
3. Novo Nordisk A/S | History, Structure, Products & Facts | Britannica Money, accessed July 25, 2025, https://www.britannica.com/money/Novo-Nordisk
4. Valuation of Novo Nordisk A/S 5th February 2015 – CBS Research Portal, accessed July 25, 2025, https://research.cbs.dk/files/58450227/Jesper_Boelt_Barslund.pdf
5. Business strategy: ‘Our focus is our strength’ – Integrated Reporting Examples Database, accessed July 25, 2025, https://examples.integratedreporting.ifrs.org/wp-content/uploads/2022/07/Novo-Nordisk_Annual-Report-2013_pp16-19.pdf
6. Novo Nordisk Leads in Diabetes, Obesity Therapies – Intelligent Investor, accessed July 25, 2025, https://www.intelligentinvestor.com.au/investment-news/novo-nordisk-leads-in-diabetes-obesity-therapies/152591
7. third quarter of 2024 – SEC.gov, accessed July 25, 2025, https://www.sec.gov/Archives/edgar/data/353278/000162828024002639/caq42023.htm
8. Financial statement – SEC.gov, accessed July 25, 2025, https://www.sec.gov/Archives/edgar/data/353278/000162828023028728/caq22023.htm
9. Document – SEC.gov, accessed July 25, 2025, https://www.sec.gov/Archives/edgar/data/353278/000162828024035364/caq22024.htm
10. Novo Nordisk Annual Report 2023 (PDF), accessed July 25, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2024/novo-nordisk-annual-report-2023.pdf
11. Q4 2024_Full presentation – Novo Nordisk, accessed July 25, 2025, https://investor.novonordisk.com/q4-2024full-presentation/
12. What are the top-selling drugs of Novo Nordisk? – Patsnap Synapse, accessed July 25, 2025, https://synapse.patsnap.com/article/what-are-the-top-selling-drugs-of-novo-nordisk
13. Novo Nordisk Annual Report 2024, accessed July 25, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf
14. NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now? | Nasdaq, accessed July 25, 2025, https://www.nasdaq.com/articles/nvo-vs-lly-which-obesity-powerhouse-stronger-bet-now
15. Novo Nordisk Diabetes Pipeline Analysis | Ozmosi Pharma Data, accessed July 25, 2025, https://www.ozmosi.com/diabetes-pipeline-analysis-novo-nordisk/
16. How Financialization Drives Pharmaceutical Patent Abuse and Health Inequities for GLP-1 Therapies – I-MAK, accessed July 25, 2025, https://www.i-mak.org/glp-1/
17. What is the patent landscape for Novo Nordisk’s semaglutide products, Ozempic, Wegovy and Rybelsus? – Markman Advisors, accessed July 25, 2025, https://www.markmanadvisors.com/blog/2025/2/7/what-is-the-patent-landscape-for-novo-nordisks-semaglutide-products-ozempic-wegovy-and-rybelsus
18. Product supply | Novo Nordisk, accessed July 25, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P3-Product-Supply.pdf
19. Product Supply – Novo Nordisk, accessed July 25, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P3-Product-supply-updated.pdf
20. Obesity Market Review – July 8, 2024 – Stifel, accessed July 25, 2025, https://www.stifel.com/newsletters/investmentbanking/bal/marketing/healthcare/biopharma_timopler/stifelobesityupdate_july2024.pdf
21. Novo Nordisk | Pharmaceutical Industry Case Study | Blue Ocean Strategy Example, accessed July 25, 2025, https://www.blueoceanstrategy.com/blue-ocean-strategy-examples/novo-nordisk/
22. Diabetes Drugs Market Share, Growth | Global Report [2032], accessed July 25, 2025, https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570
23. Diabetes Care Market Size to worth to Reach USD 62.73 Billion by 2032, Coherent Market Insights – BioSpace, accessed July 25, 2025, https://www.biospace.com/press-releases/diabetes-care-market-size-to-worth-to-reach-usd-62-73-billion-by-2032-coherent-market-insights
24. Obesity Treatment Market Size, Share | Industry Report, 2030, accessed July 25, 2025, https://www.grandviewresearch.com/industry-analysis/obesity-treatment-devices-and-therapeutics-market
25. Weight Loss Drug Market Could Reach $150 Billion Globally | Morgan Stanley, accessed July 25, 2025, https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth
26. Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData – Fierce Pharma, accessed July 25, 2025, https://www.fiercepharma.com/marketing/lillys-zepbound-expected-surpass-novos-wegovy-dominate-obesity-market-globaldata
27. With compounders out of the way, Lilly and Novo go after each other …, accessed July 25, 2025, https://www.pharmavoice.com/news/eli-lilly-novo-nordisk-compound-glp1-earnings/747046/
28. As Novo and Lilly Focus on a Few Big Markets, Sanofi Seeks Global …, accessed July 25, 2025, https://www.pharmalive.com/as-novo-and-lilly-focus-on-a-few-big-markets-sanofi-seeks-global-reach-for-diabetes-glp-1-drug/
29. Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?, accessed July 25, 2025, https://www.morningstar.com/stocks/obesity-drugs-can-new-firms-take-market-share-eli-lilly-novo-nordisk
30. Is Novo Nordisk’s Next Generation Obesity Pipeline a Game Changer? – Nasdaq, accessed July 25, 2025, https://www.nasdaq.com/articles/novo-nordisks-next-generation-obesity-pipeline-game-changer
31. Eli Lilly’s earnings, shares lifted by obesity drug sales | BioPharma Dive, accessed July 25, 2025, https://www.biopharmadive.com/news/lilly-2024-sales-obesity-mounjaro-zepbound/739392/
32. Big pharma prepares for next patent cliff as blockbuster drugs …, accessed July 25, 2025, https://chaindrugreview.com/big-pharma-prepare-for-next-patent-cliff-as-blockbuster-drugs-revenue-losses-loom-says-globaldata/
33. Generic Ozempic Availability – Drugs.com, accessed July 25, 2025, https://www.drugs.com/availability/generic-ozempic.html
34. Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk’s weight-loss drugs, accessed July 25, 2025, https://parolaanalytics.com/blog/ozempic-weight-loss-patents-novo-nordisk/
35. Novo Nordisk – Blog – Business & Environment – Harvard Business School, accessed July 25, 2025, https://www.hbs.edu/environment/blog/post/IFC-Novo-Nordisk
36. Our scientific approach | Novo Nordisk U.S. Website, accessed July 25, 2025, https://www.novonordisk-us.com/partnering-and-innovation/our-scientific-approach.html
37. Research and early development | Novo Nordisk, accessed July 25, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P2-Research-and-Early-Development.pdf
38. Research and early development – Novo Nordisk, accessed July 25, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P2-r-and-d-updated.pdf
39. NVO SEC Filings – Novo Nordisk A/S – Depositary Receipt (Common Stock)- Annual Report, Proxy Statement, Prospectus – Fintel, accessed July 25, 2025, https://fintel.io/sfs/us/nvo
40. R&D pipeline – Novo Nordisk, accessed July 25, 2025, https://www.novonordisk.com/science-and-technology/r-d-pipeline.html
41. Novo Nordisk Revenue 2010-2025 | NVO – Macrotrends, accessed July 25, 2025, https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/revenue
42. Key Metrics – Novo Nordisk AS ADR NVO – Morningstar, accessed July 25, 2025, https://www.morningstar.com/stocks/xnys/nvo/key-metrics
43. Novo Nordisk Net Profit Margin 2010-2025 | NVO – Macrotrends, accessed July 25, 2025, https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/profit-margins
44. Financial report for the period 1 January 2023 to 31 December 2023 Novo Nordisk’s sales increased by 31% in Danish kroner and by, accessed July 25, 2025, https://ml-eu.globenewswire.com/Resource/Download/b4ae7c0b-df06-49cd-a1b9-50d5d566e6bc
45. Novo Nordisk A/S, NOVO B:CPH financials – FT.com – Markets data, accessed July 25, 2025, https://markets.ft.com/data/equities/tearsheet/financials?s=NOVO%20B:CPH
46. Novo Nordisk ROI – Return on Investment 2010-2025 | NVO – Macrotrends, accessed July 25, 2025, https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/roi
47. Novo Nordisk ROE – Return on Equity 2010-2025 | NVO – Macrotrends, accessed July 25, 2025, https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/roe
48. Financials – Annual Report 2024 – Novo Nordisk, accessed July 25, 2025, https://annualreport.novonordisk.com/2024/strategic-aspirations/financials.html
49. Novo-Nordisk A/S (NVO) Balance Sheet – Moomoo, accessed July 25, 2025, https://www.moomoo.com/stock/NVO-US/financials-balance-sheet
50. Novo Nordisk’s semaglutide delivers in phase 3 MASH study – Fierce Pharma, accessed July 25, 2025, https://www.fiercepharma.com/pharma/novo-nordisks-semaglutide-delivers-phase-3-mash-study-teeing-filings
51. Novo Nordisk Capital Markets Day 2024 – webcasts and presentations, accessed July 25, 2025, https://www.novonordisk.com/investors/capital-markets-day-2024.html
52. What are Novo Nordisk’s recent drug deals?, accessed July 25, 2025, https://synapse.patsnap.com/article/what-are-novo-nordisks-recent-drug-deals
53. THE IMPACT OF PATENT CLIFF RISK ON NOVO NORDISK A/S: AN ERM ASSESSMENT WITH FOCUS ON TWO MAIN PRODUCTS IN THE US MARKET, accessed July 25, 2025, https://tesi.luiss.it/20591/1/672871_DE%20FRANCESCO_VITTORIANA.pdf
54. Q3 2024 presentation – Novo Nordisk, accessed July 25, 2025, https://investor.novonordisk.com/q3-2024-presentation/
55. Latest Competitive Analysis of Novo Nordisk Drug Pipeline – Patsnap Synapse, accessed July 25, 2025, https://synapse.patsnap.com/blog/latest-competitive-analysis-of-novo-nordisk-drug-pipeline
56. Novo Nordisk files annual report with the SEC – GlobeNewswire, accessed July 25, 2025, https://www.globenewswire.com/news-release/2025/02/05/3021087/0/en/Novo-Nordisk-files-annual-report-with-the-SEC.html
57. Novo Nordisk Loses Canadian Patent Protection For Blockbuster Diabetes Drug Over Unpaid $450 Fee – Slashdot, accessed July 25, 2025, https://science.slashdot.org/story/25/06/16/1438211/novo-nordisk-loses-canadian-patent-protection-for-blockbuster-diabetes-drug-over-unpaid-450-fee
58. Financials – Novo Nordisk, accessed July 25, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P12-Financials.pdf
59. Corporate strategy Purpose and sustainability | Novo Nordisk, accessed July 25, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P1-Corporate-Strategy-and-Purpose-and-Sustainability.pdf
60. Novo Holdings · Investments, accessed July 25, 2025, https://novoholdings.dk/investments/
61. Novo Nordisk A/S (NOV) Leadership & Management Team Analysis – Simply Wall St, accessed July 25, 2025, https://simplywall.st/stocks/bg/pharmaceuticals-biotech/bul-nov/novo-nordisk-shares/management
62. Novo Nordisk A/S (NVO) Leadership & Management Team Analysis …, accessed July 25, 2025, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/management
63. Novo Nordisk CEO Exit Signals Strategic Recalibration Amid Investor Pressure and Foundation Power Shift – BioPharma BoardRoom, accessed July 25, 2025, https://www.biopharmaboardroom.com/analysis/56/3341/novo-nordisk-ceo-exit-signals-strategic-recalibration-amid-investor-pressure-and-foundation-power-shift-.html
64. Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Strategic Leadership Transition – Pharmaceutical Executive, accessed July 25, 2025, https://www.pharmexec.com/view/novo-nordisk-ceo-lars-fruergaard-jorgensen-step-down-strategic-leadership-transition
65. Executive Management – Novo Nordisk, accessed July 25, 2025, https://www.novonordisk.com/about/executive-management.html
66. Corporate governance – Novo Nordisk, accessed July 25, 2025, https://www.novonordisk.com/about/corporate-governance.html
67. Novo Nordisk (NVO) Statistics & Valuation – Stock Analysis, accessed July 25, 2025, https://stockanalysis.com/stocks/nvo/statistics/
68. Novo Nordisk | NVO – PE Price to Earnings – Trading Economics, accessed July 25, 2025, https://tradingeconomics.com/nvo:us:pe
69. PE Ratio – Novo Nordisk A/S – Wisesheets, accessed July 25, 2025, https://www.wisesheets.io/pe-ratio/NONOF
70. PE Ratio – Novo Nordisk A/S – Wisesheets, accessed July 25, 2025, https://www.wisesheets.io/pe-ratio/NVO
71. EV / EBITDA For Novo Nordisk A/S (NVO) – Finbox, accessed July 25, 2025, https://finbox.com/NYSE:NVO/explorer/ev_to_ebitda_ltm/
72. LLY – ELI LILLY PE ratio, current and historical analysis – FullRatio, accessed July 25, 2025, https://fullratio.com/stocks/nyse-lly/pe-ratio
73. NVO Stock Price Quote – Novo Nordisk AS ADR – Morningstar, accessed July 25, 2025, https://www.morningstar.com/stocks/xnys/nvo/quote
74. EV / EBITDA For Eli Lilly and Company (LLY) – Finbox, accessed July 25, 2025, https://finbox.com/NYSE:LLY/explorer/ev_to_ebitda_ltm/
75. LLY EV/EBITDA – Eli Lilly and Co – Alpha Spread, accessed July 25, 2025, https://www.alphaspread.com/security/nyse/lly/relative-valuation/ratio/enterprise-value-to-ebitda